Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
EWTX Stock Chart & Stats
$32.82
-$0.39(-1.54%)
At close: 4:00 PM EST
$32.82
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$11.50 - $34.00
Previous CloseN/A
Volume107.81K
Average Volume (3M)858.48K
Market Cap
$3.52B
Enterprise Value$3.46B
Total Cash (Recent Filing)$530.11M
Total Debt (Recent Filing)$3.99M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
May 07, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding107,270,520
10 Day Avg. Volume736,211
30 Day Avg. Volume858,482
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-19.30
Forecast
1Y Price Target
$44.17Price Target Upside34.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development — EDG-7500Full Part D data from the CIRRUS-HCM trial could reduce clinical risk for EDG-7500 and clarify a Phase 3 study design, strengthening confidence in the program's advancement.
Financial Strength And Development RunwayA strong balance sheet enables continued advancement of late-stage and early-stage candidates and supports investment in commercial infrastructure ahead of potential product launches.
Regulatory And Commercial Potential — SevasemtenSevasemten's prior separations in functional assessments versus natural history and supportive biomarker signals position it to support a regulatory submission and potentially become the first approved therapy for Becker muscular dystrophy.
Bears Say
Clinical Trial Design RiskInfeasibility of prolonged placebo controls could complicate interpretation of long-term comparative efficacy for key trials, reducing clarity of trial outcomes.
Development Cost And Timeline RiskNeed for alternative trial designs and extra statistical analyses to address lack of placebo control can increase trial complexity, raising development costs and potentially delaying timelines.
Regulatory UncertaintyReliance on non-placebo comparators or historical controls for extended-duration studies may increase regulatory scrutiny and make approval decisions less certain.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $11.50 and its highest was $34.00 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $3.52B.
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.436 by -$0.034.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -0.49.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 107,270,520 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.436. Following the earnings report the stock price went down -1.527%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.17 (34.58% Upside)
$44.17 (34.58% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $208.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
183.66%
12-Months-Change
Fundamentals
Return on Equity
-31.97%
Trailing 12-Months
Asset Growth
13.51%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$44.17
▲(34.58% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
1.38% Insiders
11.57% Mutual Funds
76.36% Other Institutional Investors
2.03% Public Companies and
Individual Investors